SequelSEC

Actinium Pharmaceuticals, Inc. ATNM

Pharmaceutical Preparations · CIK 0001388320 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$35.00M
Fiscal year ended 2026-06-30
Operating income
$27.56M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Actinium Pharmaceuticals, Inc. (ATNM) reported revenue of $35.00M and net income of $27.90M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Actinium Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Actinium Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-12-312025-09-302023-12-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
Revenue$35.00M$0$90.00KUnavailable$0$45.00K$45.00K$940.00K$23.00K$233.00K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income$27.56M-$6.41M-$5.69MUnavailable-$11.29M-$9.80M-$7.85M-$5.16M-$8.05M-$6.47M
Net income$27.90M-$5.94M-$5.13MUnavailable-$10.65M-$9.47M-$7.77M-$5.13M-$8.01M-$6.42M
Research & development$5.38M$4.30M$4.25MUnavailable$7.33M$6.77M$4.66M$4.37M$5.42M$4.71M
Weighted-average diluted sharesshares 31.41MUnavailableshares 31.20MUnavailableUnavailableshares 25.16Mshares 23.73Mshares 22.14MUnavailableshares 21.54M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$0.89Unavailable$-0.16UnavailableUnavailable$-0.38$-0.33$-0.23Unavailable$-0.30
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$2.06M$2.12M$1.53MUnavailable$3.96M$3.07M$3.23M$1.74M$2.66M$1.99M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Actinium Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-12-312025-09-302023-12-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
Cash & equivalents$36.47M$48.00M$53.39M$76.68M$108.91M$111.82M$116.33M$72.02M$77.83M$82.03M
Total assets$40.16M$51.78M$56.15M$81.44M$114.19M$116.82M$121.80M$74.56M$80.39M$84.48M
Current assets$37.74M$49.38M$54.37M$78.26M$110.94M$113.42M$118.30M$74.05M$79.75M$83.26M
Total liabilities$9.86M$43.94M$42.37M$45.07M$47.71M$45.56M$43.62M$5.72M$6.84M$4.19M
Current liabilities$9.26M$7.97M$6.83M$8.49M$10.63M$8.35M$6.28M$5.72M$6.84M$4.19M
Total equity incl. NCI$30.30M$7.83M$13.78M$36.38M$66.48M$71.26M$78.18M$68.84M$73.54M$80.28M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Actinium Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-12-312025-09-302023-12-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
Operating cash flowUnavailable-$5.29MUnavailableUnavailable-$7.78M-$5.72M$27.92M-$5.78M-$5.05M-$5.59M
Capital expendituresUnavailableUnavailableUnavailableUnavailable$16.00K$73.00K$270.00K$7.00K$0$68.00K
Investing cash flowUnavailableUnavailableUnavailableUnavailable-$16.00K-$73.00K-$270.00K-$7.00K$0-$68.00K
Financing cash flowUnavailable-$3.00KUnavailableUnavailable$4.89M$1.58M$16.66M-$22.00K$801.00K$5.78M
Net change in cashUnavailableUnavailableUnavailableUnavailable-$2.90M-$4.21M$44.31M-$5.81M-$4.25M$120.00K
Stock-based compensationUnavailable$10.00KUnavailableUnavailable$979.00K$970.00K$425.00K$421.00K$448.00K$411.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailable-$442.00KUnavailableUnavailable$161.00K$221.00K$180.00K$137.00K$137.00K$133.00K

Derived

Actinium Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-12-312025-09-302023-12-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
Free cash flowUnavailableUnavailableUnavailableUnavailable-$7.79M-$5.79M$27.65M-$5.79M-$5.05M-$5.66M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin78.8%Unavailable-6324.4%UnavailableUnavailable-21775.6%-17444.4%-549.4%-34991.3%-2776.4%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailable-12862.2%61440.0%-615.7%-21965.2%-2427.5%
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailable2155.6%944.4%44.8%1947.8%176.4%
Current ratio4.08x6.20x7.96x9.21x10.44x13.58x18.83x12.94x11.66x19.87x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable-100.0%-80.7%-83.1%51.1%UnavailableUnavailable
Net margin79.7%Unavailable-5701.1%UnavailableUnavailable-21053.3%UnavailableUnavailable-34826.1%-2756.7%
R&D / revenue15.4%Unavailable4720.0%UnavailableUnavailable15046.7%10360.0%464.8%23547.8%2020.6%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailable162.2%600.0%0.7%0.0%29.2%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ATNM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.